Physician profile
Ben D Coffey
NPI 1669470621
$14,388.77
in general payments reported to CMS, 2019-2025
56 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $1,377 · 2021: $1,981 · 2022: $2,386 · 2023: $2,108 · 2024: $2,406 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,958.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,632.47 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,423.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,218.93 | 2020-2025 | Vraylar, Viberzi, Linzess |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,099.81 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $875.19 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $751.66 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $743.08 | 2019-2025 | |
| Amgen INC. | $675.33 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $610.49 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.74 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $455.76 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $391.06 | 2022-2025 | |
| Lundbeck LLC | $299.30 | 2023-2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $269.48 | 2024-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $266.22 | 2020-2025 | Zoryve, Livalo, Seglentis |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.